#MSVirtual2020 – New Safety, Efficacy Data on Mavenclad, Rebif and Evobrutinib on Way

#MSVirtual2020 – New Safety, Efficacy Data on Mavenclad, Rebif and Evobrutinib on Way
4
(6)

EMD Serono will present new data from programs assessing the efficacy and safety of Mavenclad (cladribine) and Rebif (interferon beta-1a), as well as investigative evobrutinib in treating relapsing forms of multiple sclerosis (MS) at the MSVirtual2020 meeting.

Findings are part of 54 abstracts being presented by EMD Serono, known as Merck KGaA outside North America, at the Sept. 11–13 meeting.

They include real-world data on Mavenclad, a review of Rebif’s use by pregnant patients and its safety in people with viral respiratory infections, and preclinical and early clinical trial efficacy results on evobrutinib.

“The broad range of research revealed through these data demonstrate our strategic approach to advancing the MS treatment landscape through new medicines and patient-focused research initiatives,” Luciano Rossetti, global head of Research & Development at EMD Serono, said in a press release.

Regarding Mavenclad, the company’s oral, short-course therapy for those with active and relapsing forms of MS, new data comes from the Phase 3 CLARITY trial (NCT00213135) and its extension study (NCT00641537) on the therapy’s long-term efficacy at reducing the incidence of cumulative MS relapses over five years.

Findings from a post-hoc analysis of CLARITY investigating the five-year effects of Mavenclad on patients’ disability — assessed by the Expanded Disability Status Scale (EDSS) — will also be presented.

The company will also present new data from two Phase 4 trials of Mavenclad — MAGNIFY (NCT03364036) and CLARIFY (NCT03369665) — including the clinical outcomes of MS patients infected with COVID-19 while taking the medication during these trials.

Long-term efficacy and real-world data from another Phase 4 Mavenclad trial, called CLASSIC MS (NCT03961204), will be presented as part of the late-breaker sessions taking place on Sept. 25–26.

Updated post-approval safety data covering both Mavenclad and Rebif in treating MS, including a look at the risk of respiratory infections of concern during the ongoing pandemic.

“Much of our data provide insights on how Mavenclad and Rebif affect the risk of respiratory viral infections and COVID-19 outcomes in MS patients. These insights will help support clinicians as they make treatment decisions for their patients living with MS,” Rossetti said.

New data will also come from an open-label extension of a Phase 2 trial (NCT02975349) assessing the long-term efficacy of its investigational, oral BTK inhibitor, called evobrutinib, in patients with relapsing forms of MS.

EMD Serono will also present findings from a preclinical study of evobrutinib’s potential in lowering inflammation in the central nervous system (CNS; composed by the brain and spinal cord), which is thought to be one of the key drivers of MS.

Joana holds a BSc in Biology, a MSc in Evolutionary and Developmental Biology and a PhD in Biomedical Sciences from Universidade de Lisboa, Portugal. Her work has been focused on the impact of non-canonical Wnt signaling in the collective behavior of endothelial cells — cells that made up the lining of blood vessels — found in the umbilical cord of newborns.
Total Posts: 1,053
Patrícia holds her PhD in Medical Microbiology and Infectious Diseases from the Leiden University Medical Center in Leiden, The Netherlands. She has studied Applied Biology at Universidade do Minho and was a postdoctoral research fellow at Instituto de Medicina Molecular in Lisbon, Portugal. Her work has been focused on molecular genetic traits of infectious agents such as viruses and parasites.
×
Joana holds a BSc in Biology, a MSc in Evolutionary and Developmental Biology and a PhD in Biomedical Sciences from Universidade de Lisboa, Portugal. Her work has been focused on the impact of non-canonical Wnt signaling in the collective behavior of endothelial cells — cells that made up the lining of blood vessels — found in the umbilical cord of newborns.
Latest Posts
  • T-cells and MS
  • MS survey
  • Tysabri, MS symptoms

How useful was this post?

Click on a star to rate it!

Average rating 4 / 5. Vote count: 6

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

We are sorry that this post was not useful for you!

Let us improve this post!

Tell us how we can improve this post?